Merck Sharp & Dohme LLC Credit Rating

Resultados 1 - 50 de 88

Página de 2 Next

Filtrar por:

Fecha	Tipo de Informe	Título	Fuente
08 Apr 2024	Rating Action	Moody's Ratings affirms Merck & Co.'s A1 ratings; revises outlook to positive	Moody's Investors Service
27 Jul 2023	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
24 Mar 2023	Rating Action	Moody's affirms Merck & Co.'s A1 rating; revises outlook to stable from negative	Moody's Investors Service
04 Oct 2022	Announcement of Periodic Review	Moody's announces completion of a periodic review for a group of Pharmaceutical issuers	Moody's Investors Service
10 Nov 2021	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.	Moody's Investors Service
04 Oct 2021	Credit Opinion	Merck & Co., Inc.: Update to credit analysis – Acceleron acquisition reduces M&A capacity	Moody's Investors Service
01 Oct 2021	Rating Action	Moody's affirms Merck's A1 ratings; revises outlook to negative	Moody's Investors Service
26 Jul 2021	Credit Opinion	Merck & Co., Inc.: Update to credit analysis – Keytruda growth and cost reductions will propel strong growth	Moody's Investors Service
29 Jan 2021	Credit Opinion	Merck & Co., Inc.: Update to credit analysis – Keytruda growth and cost reductions will propel strong growth after Organon spinoff	Moody's Investors Service
15 Dec 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.	Moody's Investors Service
06 Aug 2020	Credit Opinion	Merck & Co., Inc.: Update to credit analysis – Keytruda growth helps mitigate ongoing coronavirus impact, with Organon spin-off pending	Moody's Investors Service
06 Feb 2020	Credit Opinion	Merck & Co., Inc.: Update to credit analysis after NewCo spin-off announcement	Moody's Investors Service
05 Feb 2020	Rating Action	Moody's affirms Merck's A1/Prime-1 ratings; stable outlook	Moody's Investors Service
14 Jan 2020	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.	Moody's Investors Service
21 Nov 2019	Credit Opinion	Merck & Co., Inc.: Update to credit analysis - Keytruda will propel solid growth, but also result in declining business diversity	Moody's Investors Service
21 May 2019	Credit Opinion	Merck & Co., Inc.: Update to credit analysis - Keytruda will fuel solid growth until Januvia cliff in 2022-2023	Moody's Investors Service
15 Feb 2019	Announcement of Periodic Review	Moody's announces completion of a periodic review of ratings of Merck & Co., Inc.	Moody's Investors Service
21 Nov 2018	Credit Opinion	Merck & Co., Inc.: Update to credit analysis - strong Keytruda performance will continue, but diversification through M&A is likely	Moody's Investors Service
21 May 2018	Credit Opinion	Merck & Co., Inc.: Update to credit analysis - Strong credit metrics and cash flow but Keytruda concentration is rising	Moody's Investors Service
21 Nov 2017	Credit Opinion	Merck & Co., Inc.: Update to credit analysis -- Diverse pharmaceutical company with low financial leverage and growing oncology presence	Moody's Investors Service
07 Jun 2017	Credit Opinion	Merck & Co., Inc.: Update to Discussion of Key Credit Factors	Moody's Investors Service
08 Dec 2016	Credit Opinion	Merck & Co., Inc.: Update to Discussion of Key Credit Factors	Moody's Investors Service
08 Jun 2016	Credit Opinion	Merck & Co., Inc.: Update to Discussion of Key Credit Factors	Moody's Investors Service
08 Dec 2015	Rating Action	Moody's upgrades Merck's non-guaranteed debt to A1 from A2	Moody's Investors Service
05 Feb 2015	Rating Action	Moody's assigns A2 rating to Merck & Co.'s new unsecured notes	Moody's Investors Service
08 Dec 2014	Rating Action	Moody's affirms Merck & Co.'s ratings; outlook stable	Moody's Investors Service
09 Oct 2014	Credit Focus	: Merck and Pfizer: Peer Comparison	Moody's Investors Service
06 Oct 2014	Rating Action	Moody's rates Merck's new euro notes A2; stable outlook	Moody's Investors Service
09 Jun 2014	Announcement	Moody's: Merck's Idenix acquisition is credit negative	Moody's Investors Service
06 May 2014	Announcement	Moody's: Merck's consumer products sale is credit-positive	Moody's Investors Service
13 Jan 2014	Announcement	Moody's: Merck's potential business divestitures are credit negative	Moody's Investors Service
01 Oct 2013	Announcement	Moody's: Merck restructuring is credit positive	Moody's Investors Service
14 May 2013	Rating Action	Moody's lowers Merck's guar. debt to A1 from Aa3; stable outlook	Moody's Investors Service
01 May 2013	Rating Action	Moody's reviews Merck's ratings for downgrade	Moody's Investors Service
22 Mar 2012	Announcement	Moody's Disclosures on Credit Ratings of Merck & Co., Inc.	Moody's Investors Service
20 Jun 2011	Rating Action	Moody's assigns A1 to Merck's new credit facilities	Moody's Investors Service
07 Dec 2010	Rating Action	Moody's rates Merck's new sr. notes A1; stable outlook	Moody's Investors Service
13 Oct 2010	Special Comment	Global Pharmaceutical Issuer Scorecard	Moody's Investors Service
24 Jun 2010	Rating Action	Moody's assigns A1 rating to Merck's new credit facility	Moody's Investors Service
26 Mar 2010	Credit Opinion	Merck Sharp & Dohme Corp.	Moody's Investors Service
17 Nov 2009	Rating Action	Moody's assigns P-1 to Merck's new CP program; stable outlook	Moody's Investors Service
05 Nov 2009	Rating Action	Moody's affirms Merck, upgrades Schering; outlook now stable	Moody's Investors Service
02 Jul 2009	Analysis	Merck & Co., Inc.	Moody's Investors Service
22 Jun 2009	Rating Action	Moody's rates Merck's new notes Aa3; negative outlook	Moody's Investors Service
24 Apr 2009	Covenant Quality Assessment	Merck & Co., Inc. - Notes and debentures issued under Indenture dated as of April 1, 1991; Coupon and maturity range: 4.375%-6.4%, 2011-2044	Moody's Investors Service
24 Mar 2009	Announcement	Moody's says Merck's Aa3 not currently affected by DOJ letter	Moody's Investors Service
24 Mar 2009	Issuer Comment	Moody's says Merck's Aa3 not currently affected by DOJ letter	Moody's Investors Service
09 Mar 2009	Rating Action	Moody's affirms Merck's Aa3, revises outlook to negative	Moody's Investors Service
25 Aug 2008	Rating Action	Moody's revises Merck's outlook to stable, affirms Aa3 ratings	Moody's Investors Service
22 Jul 2008	Issuer Comment	Moody's comments on Merck's rating outlook post-SEAS	Moody's Investors Service

Resultados 1 - 50 de 88

Página de 2 Next

Informes & Calificaciones

Productos & Soluciones

Noticias & Eventos

Usuarios Registrados

No se ha registrado?

Moody's Integrity Hotline

Via the Internet:

By telephone from the United States:

By telephone from outside the United States: